Epstein-Barr virus antigen–Major Histocompatibility Complex (EBV-MHC)

Epstein-Barr virus (EBV) antigen–Major Histocompatibility Complex (MHC) complexes are molecular assemblies on the surface of EBV-infected or EBV-transformed cells that signal the presence of the virus to the immune system. These complexes are formed when viral proteins, such as Epstein-Barr nuclear antigens (EBNAs) or latent membrane proteins (LMPs), are processed into short peptides and loaded onto MHC Class I or Class II molecules (Nature Reviews Immunology, 2020). In the context of EBV-associated diseases like post-transplant lymphoproliferative disorder (PTLD) and various lymphomas, these complexes serve as critical therapeutic targets for adoptive T-cell therapies and engineered T-cell receptor (TCR) products (Blood, 2022). Drugs like Tabelecleucel utilize donor-derived T-cells that specifically recognize these EBV-MHC complexes to induce targeted apoptosis of the malignant or infected cells (The Lancet Oncology, 2022). Because these targets are virally derived, they offer a high degree of specificity, potentially reducing the risk of damage to healthy, non-infected tissues. However, therapeutic challenges include the requirement for HLA matching between the drug product and the patient, as well as the potential for the virus to downregulate MHC expression to evade immune detection (Journal of Virology, 2019).

Other names

EBV peptide-HLA complexEBV-pMHCEpstein-Barr virus antigen-HLA complexEBV-specific peptide-MHCEBV-Ag-MHC

Recognition of viral peptide-MHC complexes by T-cell receptors (TCRs) on cytotoxic T-lymphocytes (CTLs) or engineered T-cells, leading to the targeted lysis of EBV-infected or transformed cells.